Related Experiment Video
Updated: Jun 9, 2026
06:27
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
Management of diffuse low-grade cerebral gliomas
Vikram C Prabhu1, Ahmad Khaldi, Kevin P Barton
1Department of Neurological Surgery, Stritch School of Medicine, Loyola University Medical Center, 2160 South 1st Avenue, Maywood, IL 60123, USA. vprabhu@lumc.edu
Neurologic Clinics
|September 7, 2010
Summary
World Health Organization grade II gliomas (GIIG) are slow-growing brain tumors. Predicting malignant transformation and survival involves analyzing genetic, histopathologic, clinical, and radiographic factors.
Area of Science:
- Neuro-oncology
- Pathology
Background:
- World Health Organization grade II gliomas (GIIG) are diffuse, slow-growing primary neuroectodermal tumors of the central nervous system.
- GIIG predominantly affect young individuals, with a slight predilection for White males, often presenting with seizures and rarely neurologic deficits.
Purpose of the Study:
- To emphasize the essential role of accurate pathologic diagnosis for unpredictable GIIG natural history.
- To highlight the evolving management strategies focusing on maximal safe surgical resection for diagnosis, symptom improvement, tumor burden reduction, and adjuvant therapy guidance.
Main Methods:
- Magnetic resonance imaging (MRI) is the primary diagnostic tool for detecting GIIG, frequently located in the frontal and temporal lobes.
- Surgical resection aims for maximal safe tumor removal to facilitate accurate diagnosis and treatment planning.
- Radiation and chemotherapy are standard adjuvant therapies, with efficacy dependent on tumor histology and balanced against potential complications.
Main Results:
- Progression of GIIG to malignant gliomas is associated with identifiable genetic, histopathologic, clinical, and radiographic changes.
- Pretreatment and treatment-related factors can predict the risk of malignant transformation and subsequent patient survival.
Conclusions:
- Accurate diagnosis and risk stratification are crucial for managing GIIG.
- Understanding factors influencing malignant transformation and survival is key to optimizing patient outcomes for World Health Organization grade II gliomas.
